Spots Global Cancer Trial Database for mixed phenotype acute leukemia

Every month we try and update this database with for mixed phenotype acute leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	NCT04128501	Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... T Acute Lymphob... Therapy-Related...	Azacitidine Venetoclax	18 Years - 75 Years	M.D. Anderson Cancer Center
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS	NCT02921061	Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult...	Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia	NCT01887587	Relapsed or Ref... Relapsed or Ref... Mixed Phenotype...	MLN9708 Vincristine Doxorubicin Dexamethasone	18 Years -	Medical College of Wisconsin
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases	NCT06013423	Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid...	Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ...	6 Months - 65 Years	Fred Hutchinson Cancer Center
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma	NCT06289673	Acute Lymphobla... Lymphoblastic L... Mixed Phenotype...	Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine	1 Year - 18 Years	St. Jude Children's Research Hospital
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma	NCT06289673	Acute Lymphobla... Lymphoblastic L... Mixed Phenotype...	Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine	1 Year - 18 Years	St. Jude Children's Research Hospital
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	NCT05316701	Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Undifferentiate... Myelodysplastic... Acute Leukemia Therapy-Related...	Orca-T Standard-of-Car...	18 Years - 65 Years	Orca Biosystems, Inc.
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)	NCT05322850	Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Acute Undiffere... Chronic Myeloid... Chronic Myeloid... Chronic Myeloid...	Orca-Q	- 50 Years	University of Florida
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation	NCT03843528	Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom...	Vorinostat Azacitidine Inj...	1 Year - 21 Years	Johns Hopkins All Children's Hospital
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies	NCT05476770	Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere...	Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone	1 Year - 21 Years	Therapeutic Advances in Childhood Leukemia Consortium
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
Management of Mixed-Phenotype Acute Leukemia in the East of France	NCT03599869	Mixed Phenotype...		18 Years -	Central Hospital, Nancy, France
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies	NCT05476770	Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere...	Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone	1 Year - 21 Years	Therapeutic Advances in Childhood Leukemia Consortium
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation	NCT03843528	Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom...	Vorinostat Azacitidine Inj...	1 Year - 21 Years	Johns Hopkins All Children's Hospital
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	NCT02828358	Acute Leukemia ... B Acute Lymphob... Mixed Phenotype...	Azacitidine Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Hydrocortisone ... Laboratory Biom... Leucovorin Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Pharmacological... Prednisolone Thioguanine Vincristine Vincristine Sul...	- 364 Days	National Cancer Institute (NCI)
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation	NCT04065399	Acute Myeloid L... Acute Lymphobla... Mixed Lineage A... Mixed Phenotype... Acute Leukemia ...	revumenib cobicistat	30 Days -	Syndax Pharmaceuticals
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL	NCT04872478	Acute Myeloid L... Acute Lymphobla... Mixed Phenotype...	MRX-2843	12 Years -	Meryx, Inc.
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia	NCT05327894	Acute Lymphobla... Mixed Phenotype...	Blinatumomab Blinatumomab	1 Day - 365 Days	Princess Maxima Center for Pediatric Oncology
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia	NCT04067336	Advanced Malign... Acute Myeloid L... Mixed Lineage L... Mixed Lineage A... Acute Leukemia ... Mixed Phenotype...	Ziftomenib	18 Years -	Kura Oncology, Inc.
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies	NCT05476770	Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere...	Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone	1 Year - 21 Years	Therapeutic Advances in Childhood Leukemia Consortium
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	NCT05316701	Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Undifferentiate... Myelodysplastic... Acute Leukemia Therapy-Related...	Orca-T Standard-of-Car...	18 Years - 65 Years	Orca Biosystems, Inc.
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome	NCT05457556	Acute Lymphobla... Acute Myeloid L... Mixed Phenotype... Myelodysplastic...	Biospecimen Col... Bone Marrow Asp... Busulfan Cyclophosphamid... Echocardiograph... Fludarabine Haploidentical ... Lapine T-Lympho... Lumbar Puncture Matched Unrelat... Melphalan Methotrexate Multigated Acqu... Mycophenolate M... Myeloablative C... Quality-of-Life... Questionnaire A... Rituximab T-Cell Depletio... Tacrolimus Thiotepa Total-Body Irra...	6 Months - 21 Years	Children's Oncology Group
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia	NCT04067336	Advanced Malign... Acute Myeloid L... Mixed Lineage L... Mixed Lineage A... Acute Leukemia ... Mixed Phenotype...	Ziftomenib	18 Years -	Kura Oncology, Inc.
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	NCT04128501	Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... T Acute Lymphob... Therapy-Related...	Azacitidine Venetoclax	18 Years - 75 Years	M.D. Anderson Cancer Center
Management of Mixed-Phenotype Acute Leukemia in the East of France	NCT03599869	Mixed Phenotype...		18 Years -	Central Hospital, Nancy, France
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)	NCT05322850	Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Acute Undiffere... Chronic Myeloid... Chronic Myeloid... Chronic Myeloid...	Orca-Q	- 50 Years	University of Florida
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS	NCT02921061	Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult...	Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy	NCT03959085	B Acute Lymphob... B Lymphoblastic... Central Nervous... Mixed Phenotype... Testicular Leuk...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bone Scan Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Leucovorin Calc... Magnetic Resona... Mercaptopurine Methotrexate Pegaspargase Positron Emissi... Prednisolone Questionnaire A... Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul...	1 Year - 25 Years	Children's Oncology Group
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	NCT04904588	Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma	Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte...	1 Year -	Center for International Blood and Marrow Transplant Research
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	NCT03128034	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Mixe... Mixed Phenotype...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Pretargeted Rad... Total-Body Irra...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders	NCT03198234	AML - Acute Mye... MDS (Myelodyspl... Mixed Phenotype... NHL - Non-Hodgk... Hodgkin's Lymph... ALL	T-allo10	3 Years - 45 Years	Stanford University
Management of Mixed-Phenotype Acute Leukemia in the East of France	NCT03599869	Mixed Phenotype...		18 Years -	Central Hospital, Nancy, France
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia	NCT03957915	Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Mixed Phenotype...	INA03 administr...	18 Years -	Institut Paoli-Calmettes
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome	NCT03404193	Acute Myeloid L... Acute Myeloid L... Blastic Plasmac... Chronic Myelomo... Mixed Phenotype... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Blast... Recurrent Chron... Recurrent Mixed... Refractory Acut... Refractory Blas... Refractory Chro... Refractory Mixe...	Decitabine Laboratory Biom... Venetoclax	18 Years -	M.D. Anderson Cancer Center
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	NCT02828358	Acute Leukemia ... B Acute Lymphob... Mixed Phenotype...	Azacitidine Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Hydrocortisone ... Laboratory Biom... Leucovorin Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Pharmacological... Prednisolone Thioguanine Vincristine Vincristine Sul...	- 364 Days	National Cancer Institute (NCI)
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms	NCT04797767	Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... Myeloid Neoplas... Relapsed Acute ... Relapsed Acute ... Relapsed Mixed ... Relapsed Myeloi... Refractory Acut... Refractory Acut... Refractory Mixe... Refractory Myel... Recurrent Myelo...	Cladribine Cytarabine Mitoxantrone Recombinant Gra... Venetoclax	18 Years -	University of Washington
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	NCT05316701	Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Undifferentiate... Myelodysplastic... Acute Leukemia Therapy-Related...	Orca-T Standard-of-Car...	18 Years - 65 Years	Orca Biosystems, Inc.
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma	NCT05602194	B Acute Lymphob... B Acute Lymphob... B Acute Lymphob... Lymphoblastic L... Mixed Phenotype... T Acute Lymphob...	Biospecimen Col... Calaspargase Pe... Levocarnitine Pegaspargase Quality-of-Life...	15 Years - 40 Years	Children's Oncology Group
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	NCT04128501	Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... T Acute Lymphob... Therapy-Related...	Azacitidine Venetoclax	18 Years - 75 Years	M.D. Anderson Cancer Center
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	NCT03007147	Acute Lymphobla... B Acute Lymphob... Mixed Phenotype... T Acute Lymphob...	Allogeneic Hema... Calaspargase Pe... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Dexrazoxane Hyd... Doxorubicin Etoposide Filgrastim Ifosfamide Imatinib Mesyla... Laboratory Biom... Leucovorin Calc... Mercaptopurine Mercaptopurine Methotrexate Methylprednisol... Pegaspargase Prednisolone Questionnaire A... Therapeutic Hyd... Thioguanine Vincristine Sul...	1 Year - 21 Years	Children's Oncology Group
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study	NCT04726241	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Juvenile Myelom... Mixed Phenotype... Myelodysplastic... Myelodysplastic... Myeloid Leukemi...	Biospecimen Col...	- 22 Years	LLS PedAL Initiative, LLC

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: